Trial Profile
A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Fludrocortisone; Hydrocortisone
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- 18 Mar 2024 Status changed from recruiting to suspended (Need to update IND).
- 07 Nov 2023 Planned End Date changed from 23 Jan 2024 to 23 Jan 2025.
- 07 Nov 2023 Planned primary completion date changed from 23 Jan 2024 to 23 Jan 2025.